CAMPATH-1M T-cell depleted BMT for SCID: long-term follow-up of 19 children treated 1987–98 in a single center

Publisher Website
Google Scholar
Abstract
SCID can be cured by BMT. Depletion of mature T cells from BM has enabled HLA non-identical stem-cell transplantation. We report the outcome of 30 patients treated with 37 T-cell depleted BMT procedures using CAMPATH-1M in vitro between 1987–98 in a single center. Immune reconstitution and quality-of-life were assessed in 19 long-term survivors. All but two received pre-transplant conditioning. T-and B-cell chimerism, numbers and function were analyzed during a median follow-up of 5.3 years (range 1.33–12). The overall engraftment rate was 59%, six children required repeated BMT and the survival rate was 63%. All have donor T cells, 58% normal T-cell numbers and 14% normal T-cell function. Of’17 evaluated, 16 patients (94%) have normal IgM and IgG levels, and production of specific Abs to protein Ags, but only 5/16 (31%) have a good response to pneumococcal polysacchande. Early and late post-BMT complications were rare and there were no delayed deaths. Only one child continues on long-term i.v. Ig 4-years post-BMT. Eleven children died (37%). CAMPATH-1M T-cell depleted BMT for SCID resulted in 63%sur-vival. Deaths of 11 children were mainly due to pre-existing infections. Seventeen of 19 long-term survivors have normal immune function and good quality-of-life.